Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia 6Neoplasms 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precancerous Conditions 2Neoplasms, Plasma Cell 2Mycosis Fungoides 2Multiple Myeloma 2Monoclonal Gammopathy of Undetermined Significance 2Lymphoproliferative Disorders 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Prolymphocytic 2Leukemia, Mast-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Large Granular Lymphocytic 2Leukemia, Hairy Cell 2Leukemia, Biphenotypic, Acute 2Immunoglobulin Light-chain Amyloidosis 2

Interventions

Carboplatin 23Cisplatin 19pembrolizumab 14Paclitaxel 13Gemcitabine 12Pemetrexed 11130-nm albumin-bound paclitaxel 9Everolimus 8Cetuximab 8Fluorouracil 7Docetaxel 6Axitinib 6Albumin-Bound Paclitaxel 6osimertinib 5durvalumab 5Sunitinib 5Radiotherapy 5Nivolumab 5Erlotinib Hydrochloride 5Cyclophosphamide 5Sorafenib 4Radiation 4Irinotecan 4Ipilimumab 4vosaroxin 3Radiotherapy, Intensity-Modulated 3Octreotide 3Bevacizumab 31-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3trifluridine tipiracil drug combination 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma × Darbepoetin alfa × Clear all
NCT00989092 2014-01-29

Darbepoetin Alfa and Anemia of Cancer

Amgen

Phase 2 Terminated
287 enrolled 21 charts
Classical hematology

Anemia, Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡